

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol* 2008;26:3063–3072.
2. de Herder WW, Kwekkeboom DJ, Feelders RA, et al. Somatostatin receptor imaging for neuroendocrine tumors. *Pituitary* 2006;9:243–248.
3. Fraenkel M, Kim MK, Faggiano A, et al. Epidemiology of gastroenteropancreatic neuroendocrine tumours. *Best Pract Res Clin Gastroenterol* 2012;26:691–703.
4. Cross AJ, Hollenback AR, Park Y. A large prospective study of risk factors for adenocarcinomas and malignant carcinoid tumors of the small intestine. *Cancer Causes Control* 2013;24:1737–1746.
5. Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). *Ann Oncol* 2013;24:3040–3044.
6. Strosberg J. Evolving treatment strategies for management of carcinoid tumors. *Curr Treat Options Oncol* 2013;14:374–388.
7. Bosman FT, Carneiro F, Hruban RH, et al., eds. *WHO Classification of Tumours of the Digestive System*. 4th ed. Lyon: International Agency for Research on Cancer; 2010.
8. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. *Am J Surg Pathol* 2010;34:300–313.
9. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. *Pancreas* 2010;39:707–712.
10. Banck MS, Kanwar R, Kulkarni AA, et al. The genomic landscape of small intestine neuroendocrine tumors. *J Clin Invest* 2013;123:2502–2508.
11. Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. *Pancreas* 2013;42:557–577.
12. Kulke MH, Benson AB 3rd, Bergsland E, et al. Neuroendocrine tumors. *J Natl Compr Canc Netw* 2012;10:724–764.
13. Soyer P, Dohan A, Eveno C, et al. Carcinoid tumors of the small-bowel: evaluation with 64-section CT-enteroclysis. *Eur J Radiol* 2013;82:943–950.
14. Edge SB, Byrd DR, Compton CC, et al., eds. *AJCC Cancer Staging Manual*. 7th ed. New York: Springer; 2010.
15. Strosberg JR, Weber JM, Feldman M, et al. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. *J Clin Oncol* 2013;31:420–425.
16. Chagpar R, Chiang YJ, Xing Y, et al. Neuroendocrine tumors of the colon and rectum: prognostic relevance and comparative performance of current staging systems. *Ann Surg Oncol* 2013;20:1170–1178.
17. Chambers AJ, Pasiaka JL, Dixon E, et al. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. *Surgery* 2008;144:645–651, discussion 651–653.
18. Dixon JL, Borgaonkar SP, Patel AK, et al. Thymic neuroendocrine carcinoma producing ectopic adrenocorticotropic hormone and Cushing's syndrome. *Ann Thorac Surg* 2013;96:e81–83.
19. Hunt BM, Horton MP, Vallieres E. Bronchogenic carcinoid tumours that are 18F-fluorodeoxyglucose avid on positron emission tomography. *Eur J Cardiothorac Surg* 2014;45:527–530.
20. Florez JC, Shepard JA, Kradin RL. Case records of the Massachusetts General Hospital. Case 17-2013. A 56-year-old woman with poorly controlled diabetes mellitus and fatigue. *N Engl J Med* 2013;368:2126–2136.
21. Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. *Gastroenterol Res Pract* 2012;2012:287825.
22. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. *Eur J Endocrinol* 2013;168:185–193.
23. Nikou GC, Toubanakis C, Moulakakis KG, et al. Carcinoid tumors of the duodenum and the ampulla of Vater: current diagnostic and therapeutic approach in a series of 8 patients. Case series. *Int J Surg*. 2011;9:248–253.
24. Reissman P, Shmailov S, Grozinsky-Glasberg S, et al. Laparoscopic resection of primary midgut carcinoid tumors. *Surg Endosc* 2013;27:3678–3682.
25. Norlen O, Stalberg P, Oberg K, et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. *World J Surg* 2012;36:1419–1431.
26. Bartlett EK, Roses RE, Gupta M, et al. Surgery for metastatic neuroendocrine tumors with occult primaries. *J Surg Res* 2013;184:221–227.
27. Landry CS, Woodall C, Scoggins CR, et al. Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system. *Arch Surg* 2008;143:664–670, discussion 670.
28. Deschamps L, Couvelard A. Endocrine tumors of the appendix: a pathologic review. *Arch Pathol Lab Med* 2010;134:871–875.
29. Murray SE, Lloyd RV, Sippel RS, et al. Clinicopathologic characteristics of colonic carcinoid tumors. *J Surg Res* 2013;184:183–188.
30. Weinstock B, Ward SC, Harpaz N, et al. Clinical and prognostic features of rectal neuroendocrine tumors. *Neuroendocrinology* 2013;98:180–187.
31. Planting A, Phang PT, Raval MJ, et al. Transanal endoscopic microsurgery: impact on fecal incontinence and quality of life. *Can J Surg* 2013;56:243–248.
32. Bernheim AM, Connolly HM, Pellikka PA. Carcinoid heart disease in patients without hepatic metastases. *Am J Cardiol* 2007;99:292–294.
33. Seymour N, Sawh SC. Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review. *Can J Anaesth* 2013;60:492–499.
34. Bergsland EK. The evolving landscape of neuroendocrine tumors. *Sem Oncol* 2013;40:4–22.
35. Strosberg J, Weber J, Feldman M, et al. Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors. *Gastrointest Cancer Res* 2013;6:81–85.
36. Martin-Richard M, Massuti B, Pineda E, et al. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study. *BMC Cancer* 2013;13:427.
37. O'Dorisio TM, Phan AT, Langdon RM, et al. Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a double-blind, placebo-controlled multicenter study. *J Clin Oncol* 2012;30:Abstr 4085.
38. Rinke A, Muller HH, Schadw-Bruttinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effects of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine mid-gut tumors: a report from the PROMID study group. *J Clin Oncol* 2009;27:4656–4663.
39. Kolby L, Persson G, Franzen S, et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. *Br J Surg* 2003;90:687–693.
40. Strosberg J. Neuroendocrine tumours of the small intestine. *Best Pract Res Clin Gastroenterol* 2012;26:755–773.
41. Oberg K, Casanovas O, Castano JP, et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. *Clin Cancer Res* 2013;19:2842–2849.
42. Liu E, Marincola P, Oberg K. Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations. *Ther Adv Gastroenterol* 2013;6:15–412–419.
43. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:514–523.
44. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet* 2011;378:2005–2012.
45. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. *J Clin Oncol* 2008;26:1316–1323.
46. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. *J Clin Oncol* 2008;26:3403–3410.
47. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:501–513.
48. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. *J Clin Oncol* 2006;24:401–406.
49. Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. *J Clin Oncol* 2012;30:2963–2968.
50. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol* 2008;26:2124–2130.
51. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al. 90Y-dotreotide for metastatic carcinoid refractory to octreotide. *J Clin Oncol* 2010;28:1652–1659.
52. Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. *Surgery* 2003;134:1057–1063.
53. Frilling A. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases (Br J Surg 2012; 99: 1480–1486). *Br J Surg* 2012;99:1486–1487.
54. Landry CS, Scoggins CR, McMasters KM, et al. Management of hepatic metastasis of gastrointestinal carcinoid tumors. *J Surg Oncol* 2008;97:253–258.
55. Norlen O, Stalberg P, Zedenius J, et al. Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours. *Br J Surg* 2013;100:1505–1514.
56. Henn AR, Levine EA, McNulty W, et al. Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine tumors. *AJR Am J Roentgenol* 2003;181:1005–1010.
57. Strosberg JR, Weber JM, Choi J, et al. A phase 2 clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. *Ann Oncol* 2012;23:2335–2341.
58. Kennedy A, Coldwell D, Sangro B, et al. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. *Am J Clin Oncol* 2012;35:393–398.
59. Kennedy AS, Dezar WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. *Am J Clin Oncol* 2008;31:271–279.
60. Frilling A, Malago M, Weber F, et al. Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. *Liver Transpl* 2006;12:1089–1096.
61. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. *Transplantation* 1998;66:1307–1312.